Press-release for stocks

Prices are updated after-hours

crawled date : 2022 - 08 - 11 source : Www.biospace.com

save search

Amneal launches 4 new Generic products, including Vasopressin single-dose
Published: 2022-08-11 (Crawled : 23:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M

Health Technology

| 71.97% | O: -1.91% H: 0.0% C: -5.19%
vasopressin

Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates
Published: 2022-08-11 (Crawled : 22:00) - biospace.com/
RGLS | $2.23 -1.33% -1.35% 92K

Health Technology

| 32.94% | O: 4.12% H: 1.13% C: -6.78%
therapeutics results

Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Published: 2022-08-11 (Crawled : 22:00) - biospace.com/
LCTX | $1.1 -3.51% 0.0% 740K

Health Technology

| -26.92% | O: 0.64% H: 4.46% C: -1.27%
therapeutics update results

VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
Published: 2022-08-11 (Crawled : 22:00) - biospace.com/
VTGN | $4.75 -1.66% -1.68% 150K

Health Technology

| -5.79% | O: 0.41% H: 9.27% C: 1.98%
therapeutics update results

Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results
Published: 2022-08-11 (Crawled : 22:00) - biospace.com/
GRPH 4 | $3.27 1.84% 490K

Professional, Scientific, and T...

| -15.87% | O: 2.91% H: 6.94% C: 2.06%
results

Quoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18th
Published: 2022-08-11 (Crawled : 22:00) - biospace.com/
QNRX | $0.633 -4.09% -4.27% 55K

Professional, Scientific, and T...

| -99.91% | O: -1.0% H: 15.21% C: -2.23%
report update results

argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis
Published: 2022-08-11 (Crawled : 17:00) - biospace.com/
ARGX | $375.0 -0.02% -0.02% 200K

Health Technology

| 0.22% | O: 1.76% H: 0.31% C: -1.76%
treatment approval

Bolt Hones in on ISAC programs as Toxicities Claim Preclinical Hopeful
Published: 2022-08-11 (Crawled : 17:00) - biospace.com/
GNMSF | News | $290.34 3.83% 340

Health Technology

| -16.69% | O: 9.82% H: 0.04% C: -2.54%
GMAB | News | $28.47 -0.32% -0.32% 460K

Health Technology

| -19.98% | O: 4.37% H: 2.47% C: 1.21%
preclinical

Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations
Published: 2022-08-11 (Crawled : 16:00) - biospace.com/
PASG | News | $1.27 3.25% 3.15% 39K

Health Technology

| -38.5% | O: 3.0% H: 1.94% C: -1.46%
pbft02 dementia global trial therapy

Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis- Topline Data Expected First Quarter 2023 -
Published: 2022-08-11 (Crawled : 16:00) - biospace.com/
NBRV | $1.42 1.39% 720K

Health Technology

| -70.11% | O: 2.74% H: 10.14% C: -0.87%
xenleta topline expected trial therapeutics cystic fibrosis phase 1

Entrada Therapeutics Reports Second Quarter 2022 Financial Results
Published: 2022-08-11 (Crawled : 16:00) - biospace.com/
TRDA | $12.54 -2.72% -2.79% 39K

Professional, Scientific, and T...

| 2.22% | O: 8.8% H: 0.0% C: -7.43%
therapeutics results

Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors
Published: 2022-08-11 (Crawled : 16:00) - biospace.com/
VIRX | $0.8367 -1.31% -1.33% 55K

Manufacturing

| -76.96% | O: 7.32% H: 2.17% C: 1.77%
therapeutics

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer
Published: 2022-08-11 (Crawled : 16:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| 142.62% | O: -1.18% H: 1.46% C: 0.05%
ALXO M | $16.24 4.77% 4.56% 440K

Commercial Services

| 21.19% | O: 2.97% H: 6.15% C: -1.44%
trial cancer phase 2

Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results
Published: 2022-08-11 (Crawled : 16:00) - biospace.com/
SIOX | $0.478 -20.5% 40K

Health Technology

| 36.15% | O: 1.39% H: 8.29% C: -2.86%
results

New Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Interventions
Published: 2022-08-11 (Crawled : 16:00) - biospace.com/
ABT | News | $106.89 -0.65% -0.22% 5.1M

Health Technology

| -2.43% | O: 0.52% H: 1.16% C: -0.32%
treatment blood test study train

Facing Thousands of Zantac-Related Lawsuits, GSK and Sanofi See Mass Sell-Off...
Published: 2022-08-11 (Crawled : 16:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480

Health Technology

| 7.84% | O: 0.45% H: 0.18% C: -1.47%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| 0.44% | O: -10.3% H: 0.0% C: 0.0%
sanofi

Comera Life Sciences to Present Topline Results of SEQURUS-2 Study at 14th Annual Bioprocessing Summit
Published: 2022-08-11 (Crawled : 16:00) - biospace.com/
CMRA | $0.041 70.59% 3K

n/a

| -98.6% | O: -1.05% H: 2.84% C: -1.06%
sciences topline life results study

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial
Published: 2022-08-11 (Crawled : 16:00) - biospace.com/
GLSI | $12.6 -4.11% -4.29% 29K

Health Technology

| 33.0% | O: 0.0% H: 6.17% C: -1.82%
trial

Inspira™ Technologies Reports Second Quarter 2022 Financial Results
Published: 2022-08-11 (Crawled : 15:00) - biospace.com/
IINN | $1.925 3.5% 3.38% 130K

Manufacturing

| 3.33% | O: -1.11% H: 4.35% C: 2.25%
results